BiotechTube

Tivozanib Hydrochloride + paclitaxel + Placebo

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Triple Negative Breast Cancer

Conditions

Triple Negative Breast Cancer

Trial Timeline

Nov 1, 2012 → Jun 1, 2014

NCT ID
NCT01745367

About Tivozanib Hydrochloride + paclitaxel + Placebo

Tivozanib Hydrochloride + paclitaxel + Placebo is a phase 2 stage product being developed by Astellas Pharma for Triple Negative Breast Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01745367. Target conditions include Triple Negative Breast Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01745367Phase 2Terminated

Competing Products

20 competing products in Triple Negative Breast Cancer

See all competitors
ProductCompanyStageHype Score
BBI-355 + Erlotinib + Futibatinib + BBI-825Boundless BioPhase 1
25
eFT508eFFECTOR TherapeuticsPhase 2
44
No drugDaiichi SankyoPre-clinical
23
EnzalutamideAstellas PharmaPhase 2
52
Abemaciclib + BicalutamideEli LillyPhase 2
52
Camrelizumab + Apatinib + Nab-paclitaxel + Epirubicin + CyclophosphamideJiangsu Hengrui MedicinePhase 2
52
Camrelizumab Plus Chemotherapy + placebo+chemotherapyJiangsu Hengrui MedicinePhase 3
77
Camrelizumab + Nab-Paclitaxel + CarboplatinJiangsu Hengrui MedicinePhase 2/3
65
Fluzoparib+Paclitaxel + Epirubicin+CyclophosphamideJiangsu Hengrui MedicinePhase 2
52
Camrelizumab + Nab paclitaxel + Epirubicin + CyclophosphamideJiangsu Hengrui MedicinePhase 2
52
SHR-1210 + Apatinib +FluzoparibJiangsu Hengrui MedicinePhase 1
33
Cyclophosphamide + Placebo + Doxorubicin + Paclitaxel + Carboplatin + Veliparib + PlaceboAbbViePhase 3
77
Combination of Veliparib + LapatinibAbbViePre-clinical
23
Capivasertib + ItraconazoleAstraZenecaPhase 1
33
Datopotamab Deruxtecan (Dato-DXd) + DurvalumabAstraZenecaPhase 2
52
Paclitaxel + Carboplatin + MEDI4736 + MEDI9447AstraZenecaPhase 1/2
41
KU-0059436 (AZD2281)(PARP inhibitor) + Carboplatin + KU-0059436 (AZD2281)(PARP inhibitor) + Paclitaxel + KU-0059436 (AZD2281)(PARP inhibitor) + Paclitaxel + CarboplatinAstraZenecaPhase 1
33
Capivasertib + Paclitaxel + PlaceboAstraZenecaPhase 3
77
Olaparib Oral Product + Olaparib Oral Product in combination with DurvalumabAstraZenecaPhase 2
52
Durvalumab + Capivasertib + Oleclumab + Paclitaxel + Trastuzumab deruxtecan + Datopotamab deruxtecanAstraZenecaPhase 1/2
41

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85